Cempra (CEMP +3.2%) moves up today after saying earlier that the USPTO issued a patent on May 28 relating to the company's loading dose regimen for Taksta, which will provide protection until 2029. The drug is currently undergoing a Phase 2 clinical study in patients with prosthetic joint infections, with the loading dose regimen designed so that the drug would rapidly reach therapeutic blood levels and minimize the risk of drug resistance.
Cempra (CEMP +3.2%) moves up today after saying earlier that the USPTO issued a patent on May 28...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs